Dr. Bekaii-Saab on Dosing Strategies With Regorafenib in CRC
In Partnership With:
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).
As an example, Bekaii-Saab says that out of 100 patients receiving regorafenib at the standard 160 mg regimen, 20 will remain on that dose. The majority will have to decrease treatment to 120 or possibly 80 mg, which is the lowest dose permitted. Some patients receive alternate doses or begin at a lower dose and escalate. However, alternating doses is not as effective, he adds, as there is a lack of anti-angiogenic pressure.
The ongoing ReDOS study is accruing 120 patients to compare the standard-dose strategy with an escalated-dose regimen as an approach to determine the right amount of treatment for patients with CRC.
